ArticlePloS one2024

Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis.

Denise Evans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.